UK +44 (0)1865 849841
Malaysia +60 3 2117 5193

Putting the power of proteomics in the hands of Flow Cytometry

The combination of simplicity and power is turning flow cytometry into the highest throughput protein analysis method yet developed.

Large-scale protein analysis, or proteomics, is still a relatively small discipline where the research front is driven by a few labs with unrestricted access to mass spectrometry (MS). MS is equivalent to a mainframe computer: very big, very sophisticated, and only a few people have the skills to use them.

Read More

A 14 colour antibody panel: developing a tool and demonstrating a process

One of the frustrations I have with Flow Cytometry is when companies present their amazing new findings at conferences, and it’s quite often about TMB cells. In my case, I work on these cells perhaps 20% of the time. The rest of the time I work on cells from other parts of the human body – bone marrow, lung, bronchoalveolar lavage, spleen – and in diverse animals such as mice, rats, and even sparrow, chicken, and mosquito.

Read More

Healthcare cybersecurity: risk management posture with patient care at the center

Denise Anderson is president of the Health Information Sharing and Analysis Centre (H-ISAC), USA. She spoke to us about her perspective on Healthcare Cybersecurity, the value of information sharing, and the paradigm shift the industry requires in light of new risks brought about by rapid innovation.

Read More

Identifying biomarkers to track tumour burden in patient blood

There is a huge need to identify biomarkers to discern which metastatic colorectal cancer patients will benefit from treatment using Regorafenib. Despite being the latest approved drugs for the disease, Regorafenib has limited clinical efficacy and is associated with a number of side effects. However, a lot of patients are treated with Regorafenib as it is the only treatment available for patients who cannot receive anti-EGFR treatment due to K-RAS or BRAF mutation.

Read More

Determining the fate of cells with Flow Cytometry

The ability to measure multiple forms of cell death simultaneously represents a significant development for such techniques. I have been using antibodies and more specific forms of dyes to identify mitochondrial activity and reactive oxygen in roughly fifty populations, whereas normally it would only be able to measure one at a time. I will be discussing this work at the Flow Cytometry Congress, and it could prove enormously beneficial to drug and immunotherapy development.

Read More

Using customer needs to drive Blockchain innovation

Manuela Maria Schöner, part of the Corporate Strategy & Consulting division at Boehringer Ingelheim, spoke to us recently about her work with blockchain. She described her perspective on the use of data in the industry, and how Blockchain could become a key tool in meeting the needs of the primary stakeholders: patients.

Read More

The EMA reflection paper on chronic liver disease and its implications for drug development in NASH

The European Medicines Agency published a “Reflection paper on chronic liver diseases (PBC, PSC, and NASH)” in Autumn 2018. Elmer Schabel gives a detailed display of the contents of this first regulatory guidance with regard to NASH, as well as a preliminary evaluation of the initial feedback and input received by stakeholders.

Read More

How should healthcare stakeholders differentiate hype from reality with blockchain technology?

In my previous post, I discussed the likely applications of Blockchain technology in the short, medium, and long-term future. These applications follow on from the key strategic priorities necessitated by the healthcare industry’s trend towards digital decentralized care delivery models.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive